Nanomaterials Boost CAR‐T Therapy for Solid Tumors

Abstract

T cell engineering, particularly via chimeric antigen receptor (CAR) modifications for enhancing tumor specificity, has shown efficacy in treating hematologic malignancies. The extension of CAR‐T cell therapy to solid tumors, however, is impeded by several challenges: the absence of tumor‐specific antigens, antigen heterogeneity, a complex immunosuppressive tumor microenvironment, and physical barriers to cell infiltration. Additionally, limitations in CAR‐T cell manufacturing capacity and the high costs associated with these therapies restrict their widespread application. The integration of nanomaterials into CAR‐T cell production and application offers a promising avenue to mitigate these challenges. Utilizing nanomaterials in the production of CAR‐T cells could decrease product variability and lower production expenses, positively impacting the targeting and persistence of CAR‐T cells in treatment and minimizing adverse effects. This review comprehensively evaluates the use of various nanomaterials in the production of CAR‐T cells, genetic modification, and in vivo delivery. It discusses their underlying mechanisms and potential for clinical application, with a focus on improving specificity and safety in CAR‐T cell therapy.This article is protected by copyright. All rights reserved

Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways

“…In treatment contexts, PD-L1 PTMs can contribute to tumor progression. In addition to PD-1/PD-L1 blockade, PTMs are vital for antigen presentation, CAR-T-cell therapy, and vaccine development [207]. Innovations such as multifluorescence resonance energy transfer (multi-FRET) are enhancing PTM research, offering new avenues for advancing tumor immunotherapy [208].…”

CAR-T cell therapy in advanced thyroid cancer: from basic to clinical

“…Modification of CAR-T cells by strategies targeting the tumor stroma, such as using ECM-degrading agents such as acetyl heparinase or fibroblast activating proteins ( 79 , 80 ), enhances their ability to penetrate physical barriers and thus increases aggregation in solid tumors. In addition, multidisciplinary cross-fertilization opens up new ideas to break the dilemma of insufficient immune cell infiltration in the tumor microenvironment, such as intratumoral injection ( 81 ), implantable scaffolds ( 82 ), and special biomaterials delivery ( 83 ), etc., which can enable the infused immune cells to be delivered to the tumor site more efficiently and effectively and target the tumor as well as reduce the off-target effect.…”